CMMB · Insider Trading
Chemomab Therapeutics Ltd. American Depositary Share
Every open-market purchase and sale reported by CMMB officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-01 | Neil Harris Cohen | Director | Sell | −2,304 | −$6.52K |
| 2026-06-01 | George Adi Mor | Chief Executive Officer | MIXED | −60,266 | −$20.25K |
| 2023-07-05 | Nissim Darvish | Director | A | — | — |
| 2023-06-20 | Jill M. Quigley | Director | A | +20,497 deriv. | — |
| 2023-06-16 | Sigal Fatal | Chief Financial Officer | A | — | — |
| 2023-03-23 | Claude Nicaise | Director | A | +25,561 deriv. | — |
| 2023-03-23 | Alan Charles Moses | Director | A | +25,561 deriv. | — |
| 2023-03-23 | Neil Harris Cohen | Director | A | — | — |
| 2023-03-23 | Nissim Darvish | Director | A | — | — |
| 2023-01-05 | George Adi Mor | Chief Scientific Officer | Sell | −13,800 | −$69.37K |
| 2023-01-05 | OrbiMed Israel BioFund GP Limited Partnership | 10%+ Owner | Sell | −673,800 | −$2.42M |
| 2022-11-18 | Neil Harris Cohen | Director | Sell | −2,409 | −$4.82K |
| 2022-11-17 | George Adi Mor | Chief Scientific Officer | Sell | −582,023 | −$1.21M |
| 2022-06-21 | Donald Marvin | Executive VP, CFO & COO | Buy | +500 | +$1.64K |
| 2022-05-25 | Joel Michael Maryles | Director | Buy | +433 | +$1.25K |
| 2022-05-19 | Neil Harris Cohen | Director | Buy | +2,000 | +$6.38K |
| 2022-03-21 | Donald Marvin | Executive VP, CFO & COO | Buy | +1,250 | +$5.04K |
| 2022-03-21 | Joel Michael Maryles | Director | Buy | +1,000 | +$4.34K |
| 2022-03-15 | Dale R Pfost | Chief Executive Officer | Buy | +2,500 | +$9.94K |
| 2022-03-15 | Neil Harris Cohen | Director | Buy | +6,000 | +$26.12K |
| 2022-03-14 | Nissim Darvish | Director | Buy | +1,200 | +$5.14K |
| 2022-03-09 | Claude Nicaise | Director | A | +18,704 deriv. | — |
| 2022-03-09 | Alan Charles Moses | Director | A | +18,704 deriv. | — |
| 2022-03-09 | Nissim Darvish | Director | A | +18,704 deriv. | — |
| 2022-03-09 | Neil Harris Cohen | Director | A | — | — |
| 2022-03-09 | Joel Michael Maryles | Director | A | +18,704 deriv. | — |
| 2021-12-08 | Neil Harris Cohen | Director | Buy | +2,000 | +$14.86K |
| 2021-05-10 | Sigal Fatal | Chief Financial Officer | A | +35,653 deriv. | — |
| 2021-04-21 | Alan Charles Moses | Director | A | +11,884 deriv. | — |
| 2021-04-21 | Joel Michael Maryles | Director | A | +11,884 deriv. | — |
| 2021-04-21 | Stephen P Squinto | Director | A | — | — |
| 2021-04-21 | Nissim Darvish | Director | A | +11,884 deriv. | — |
| 2021-04-21 | Claude Nicaise | Director | A | +11,884 deriv. | — |
| 2021-04-21 | Neil Harris Cohen | Director | A | — | — |
| 2021-03-26 | Neil Harris Cohen | Director | Buy | +2,409 | +$100.00K |
| 2021-03-18 | Peter Thiel | 10%+ Owner | Buy | +230,536 | — |
| 2021-03-18 | OrbiMed Israel GP Ltd. | 10%+ Owner | A | +576,340 | +$10.00M |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| George Adi Mor | Chief Executive Officer | 94,499 | $94.50K |
| Neil Harris Cohen | Director | 34,000 | $34.00K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CMMB quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.